The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group
- PMID: 9475762
- DOI: 10.1056/NEJM199802263380901
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group
Abstract
Background: Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, is not known.
Methods: In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men.
Results: During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P<0.001). Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001).
Conclusions: Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention.
Comment in
- ACP J Club. 1998 Jul-Aug;129(1):11
-
Finasteride to prevent morbidity from benign prostatic hyperplasia.N Engl J Med. 1998 Feb 26;338(9):612-3. doi: 10.1056/NEJM199802263380909. N Engl J Med. 1998. PMID: 9475770 No abstract available.
Similar articles
-
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.N Engl J Med. 1992 Oct 22;327(17):1185-91. doi: 10.1056/NEJM199210223271701. N Engl J Med. 1992. PMID: 1383816 Clinical Trial.
-
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.J Urol. 2004 Mar;171(3):1194-8. doi: 10.1097/01.ju.0000112918.74410.94. J Urol. 2004. PMID: 14767299 Clinical Trial.
-
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656. N Engl J Med. 2003. PMID: 14681504 Clinical Trial.
-
A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.Clin Ther. 2007 Jan;29(1):17-25. doi: 10.1016/j.clinthera.2007.01.018. Clin Ther. 2007. PMID: 17379044 Review.
-
[The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].Wien Med Wochenschr. 1996;146(8):165-8. Wien Med Wochenschr. 1996. PMID: 8767401 Review. German.
Cited by
-
Effect of the duration of bladder overdistention on renal function and morphology in rats.Exp Ther Med. 2013 Jun;5(6):1720-1724. doi: 10.3892/etm.2013.1028. Epub 2013 Mar 26. Exp Ther Med. 2013. PMID: 23837061 Free PMC article.
-
Update on the medical management of benign prostatic hyperplasia.Int Urol Nephrol. 2002;33(1):67-8. doi: 10.1023/a:1014405019814. Int Urol Nephrol. 2002. PMID: 12090341 Review. No abstract available.
-
Medical therapy for benign prostatic hyperplasia progression.Curr Urol Rep. 2002 Aug;3(4):269-75. doi: 10.1007/s11934-002-0047-y. Curr Urol Rep. 2002. PMID: 12149154 Review.
-
Mortality in men admitted to hospital with acute urinary retention.BMJ. 2007 Dec 8;335(7631):1164-5. doi: 10.1136/bmj.39384.556725.80. Epub 2007 Nov 8. BMJ. 2007. PMID: 17991936 Free PMC article.
-
The Clinical Benefits of Dutasteride Treatment for LUTS and BPH.Rev Urol. 2004;6 Suppl 9(Suppl 9):S22-30. Rev Urol. 2004. PMID: 16985921 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical